Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

Colin R Lindsay; Emily C Shaw; David A Moore; Doris Rassl; Mariam Jamal-Hanjani; Nicola Steele; Salma Naheed; Craig Dick; Fiona Taylor; Helen Adderley; Fiona Black; Yvonne Summers; Matt Evans; Alexandra Rice; Aurelie Fabre; William A Wallace; Siobhan Nicholson; Alex Haragan; Phillipe Taniere; Andrew G Nicholson; Gavin Laing; Judith Cave; Martin D Forster; Fiona Blackhall; John Gosney; Sanjay Popat; Keith M Kerr

doi:10.1038/s41416-021-01407-9

Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

Colin R Lindsay
, Emily C Shaw
, David A Moore
, Doris Rassl
, Mariam Jamal-Hanjani
, Nicola Steele
, Salma Naheed
, Craig Dick
, Fiona Taylor
, Helen Adderley
, Fiona Black
, Yvonne Summers
, Matt Evans
, Alexandra Rice
, Aurelie Fabre
, William A Wallace
, Siobhan Nicholson
, Alex Haragan
, Phillipe Taniere
, Andrew G Nicholson

Gavin Laing, Judith Cave, Martin D Forster, Fiona Blackhall, John Gosney, Sanjay Popat, Keith M Kerr

Research output: Contribution to journal › Review article › peer-review

Abstract

Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.

Original language	English
Pages (from-to)	1210-1216
Number of pages	7
Journal	British Journal of Cancer
Volume	125
Issue number	9
DOIs	https://doi.org/10.1038/s41416-021-01407-9
Publication status	Published - Oct 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Biomarkers, Tumor/metabolism
Carcinoma, Large Cell/metabolism
Carcinoma, Neuroendocrine/metabolism
Clinical Trials as Topic
Consensus
Humans
Lung Neoplasms/metabolism
Precision Medicine
Treatment Outcome

Access to Document

10.1038/s41416-021-01407-9

Cite this

Lindsay, C. R., Shaw, E. C., Moore, D. A., Rassl, D., Jamal-Hanjani, M., Steele, N., Naheed, S., Dick, C., Taylor, F., Adderley, H., Black, F., Summers, Y., Evans, M., Rice, A., Fabre, A., Wallace, W. A., Nicholson, S., Haragan, A., Taniere, P., ... Kerr, K. M. (2021). Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. British Journal of Cancer, 125(9), 1210-1216. https://doi.org/10.1038/s41416-021-01407-9

@article{e7f4e0de196f4bc99f4d7319ef033278,

title = "Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists",

abstract = "Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.",

keywords = "Biomarkers, Tumor/metabolism, Carcinoma, Large Cell/metabolism, Carcinoma, Neuroendocrine/metabolism, Clinical Trials as Topic, Consensus, Humans, Lung Neoplasms/metabolism, Precision Medicine, Treatment Outcome",

author = "Lindsay, \{Colin R\} and Shaw, \{Emily C\} and Moore, \{David A\} and Doris Rassl and Mariam Jamal-Hanjani and Nicola Steele and Salma Naheed and Craig Dick and Fiona Taylor and Helen Adderley and Fiona Black and Yvonne Summers and Matt Evans and Alexandra Rice and Aurelie Fabre and Wallace, \{William A\} and Siobhan Nicholson and Alex Haragan and Phillipe Taniere and Nicholson, \{Andrew G\} and Gavin Laing and Judith Cave and Forster, \{Martin D\} and Fiona Blackhall and John Gosney and Sanjay Popat and Kerr, \{Keith M\}",

note = "{\textcopyright} 2021. The Author(s).",

year = "2021",

month = oct,

doi = "10.1038/s41416-021-01407-9",

language = "English",

volume = "125",

pages = "1210--1216",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "9",

}

Lindsay, CR, Shaw, EC, Moore, DA, Rassl, D, Jamal-Hanjani, M, Steele, N, Naheed, S, Dick, C, Taylor, F, Adderley, H, Black, F, Summers, Y, Evans, M, Rice, A, Fabre, A, Wallace, WA, Nicholson, S, Haragan, A, Taniere, P, Nicholson, AG, Laing, G, Cave, J, Forster, MD, Blackhall, F, Gosney, J, Popat, S & Kerr, KM 2021, 'Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists', British Journal of Cancer, vol. 125, no. 9, pp. 1210-1216. https://doi.org/10.1038/s41416-021-01407-9

TY - JOUR

T1 - Large cell neuroendocrine lung carcinoma

T2 - consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

AU - Lindsay, Colin R

AU - Shaw, Emily C

AU - Moore, David A

AU - Rassl, Doris

AU - Jamal-Hanjani, Mariam

AU - Steele, Nicola

AU - Naheed, Salma

AU - Dick, Craig

AU - Taylor, Fiona

AU - Adderley, Helen

AU - Black, Fiona

AU - Summers, Yvonne

AU - Evans, Matt

AU - Rice, Alexandra

AU - Fabre, Aurelie

AU - Wallace, William A

AU - Nicholson, Siobhan

AU - Haragan, Alex

AU - Taniere, Phillipe

AU - Nicholson, Andrew G

AU - Laing, Gavin

AU - Cave, Judith

AU - Forster, Martin D

AU - Blackhall, Fiona

AU - Gosney, John

AU - Popat, Sanjay

AU - Kerr, Keith M

PY - 2021/10

Y1 - 2021/10

N2 - Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.

AB - Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.

KW - Biomarkers, Tumor/metabolism

KW - Carcinoma, Large Cell/metabolism

KW - Carcinoma, Neuroendocrine/metabolism

KW - Clinical Trials as Topic

KW - Consensus

KW - Humans

KW - Lung Neoplasms/metabolism

KW - Precision Medicine

KW - Treatment Outcome

U2 - 10.1038/s41416-021-01407-9

DO - 10.1038/s41416-021-01407-9

M3 - Review article

C2 - 34489586

SN - 0007-0920

VL - 125

SP - 1210

EP - 1216

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -

Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this